HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature - Wikidata - wikimedia - TriplyDB

HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature

HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature

http://www.wikidata.org/entity/Q34223664

about

Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients HER2 testing in gastric cancer: An update Gastric cancer: The times they are a-changin'HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.Induction of targeted necrosis with HER2-targeted platinum(iv) anticancer prodrugs.Prognostic role of lemur tyrosine kinase 3 in postoperative gastric cancer Correlation between HER2 Overexpression and Clinicopathological Characteristics in Gastric Cancer Patients Who Have Undergone Curative Resection.Serum HER 2 extracellular domain level is correlated with tissue HER 2 status in metastatic gastric or gastro-oesophageal junction adenocarcinoma Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas.HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.HER2 expression in gastric and oesophageal cancer: a meta-analytic review Correlations of Human Epithelial Growth Factor Receptor 2 Overexpression with MUC2, MUC5AC, MUC6, p53, and Clinicopathological Characteristics in Gastric Cancer Patients with Curative Resection.Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer.Copy Number Gains at 8q24 and 20q11-q13 in Gastric Cancer Are More Common in Intestinal-Type than Diffuse-Type HER-2 incidence in gastric cancer, its association with prognosis and clinicopathological parameters.Targeted therapies in gastric cancer and future perspectives.Identification of Serum Biomarkers for Gastric Cancer Diagnosis Using a Human Proteome Microarray.The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples.HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series.Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.HER2-positive double primary tumor of gastric and breast cancer occur synchronously in a patient: A case report.Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population.Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.Enhanced CRAd activity using enhancer motifs driven by a nucleosome positioning sequence.Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China.Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer.Personalizing therapies for gastric cancer: molecular mechanisms and novel targeted therapies Sex disparities in the association of lung adenocarcinoma with colorectal cancer.The progress of targeted therapy in advanced gastric cancer HER2-positive gastric cancer.HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives.Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects.Metastatic gastric cancer treatment: a little slow but worthy progress.Trastuzumab: a review of its use in HER2-positive advanced gastric cancer.The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.Investigational therapies targeting the ErbB family in oesophagogastric cancer.Multimodality treatment of potentially curative gastric cancer: geographical variations and future prospects.The low-abundance transcriptome reveals novel biomarkers, specific intracellular pathways and targetable genes associated with advanced gastric cancer.

P2860

Q21261244-C3D3FCD2-9B37-402B-8347-9AC1916F080D Q26746253-7C2D90C6-08A2-4169-B01C-18E56D5A14A7 Q26776195-3217AC7E-B22E-4440-BE7E-2C2F0F1C1032 Q26780318-B0B36F7F-49C7-4CEE-90A9-4E823C47A129 Q28077666-1C5D6DE8-AE63-4499-9159-E4D658C6947F Q33779412-A3C0F503-7A25-40D0-BD04-506FEB87E796 Q33850523-B9B075A4-290B-4629-A77C-D6FA3A325CCF Q33933039-3CB43229-F100-4F69-8CE3-D04707E67AA5 Q34353223-533D60BE-5D2A-4767-8C77-E86F3E3B58C5 Q34730478-E1C1D9AB-61BC-4D1D-AC1C-6AB5FD860CD6 Q34852929-EC7F14C8-8784-4411-ABB1-BFE1EE827BDD Q34981712-5EB022D3-54D8-4DDB-9EBC-57F9C325A533 Q35029025-2E160B47-B3B4-4F74-8AD2-64DF5FFEEE2A Q35594687-A1810C94-A7C3-4BC3-96F7-DEBBC89EFBF4 Q35768487-875687E9-738D-44C9-8F32-0B9E8315B968 Q35770650-B5E82C53-031A-4B51-B580-9942504A2147 Q36358687-34879786-E76C-4CCA-8E56-E59A931CDEA0 Q36471685-F66F3A87-C78C-42C5-BA7F-F5D16B857F3A Q36539497-F6531C4A-E31D-42E5-9EF2-334121CD1143 Q36613291-328844AB-5AA8-4984-8117-9255ACDF5C93 Q36655951-911F3579-F9BB-4A81-9952-1D0593B3E583 Q36770491-18AE0C41-2C57-420E-9FB0-4668A2A42077 Q36824730-BD371D6B-032E-4939-B263-D6A61345BE3B Q36897947-4E48DA6D-9749-4939-8DC2-EFE04E22032A Q36950483-C6033A1A-F857-4242-9098-AF8FAEBC7CBB Q36984452-C513624F-19FA-48D9-B314-4F8F26FDC2C0 Q37012387-D0672605-C56D-44FA-AE66-896C814B4CF9 Q37109776-7AEF1D2F-4DAB-4573-997F-61A35C53FB4B Q37241496-03159CBD-6814-4E7E-94C7-5FA24EE39172 Q37347517-8A741FB3-15AC-4E6D-804D-7C54E9087A60 Q37427269-E12D8FD8-2756-4EF0-B892-638252BB6373 Q37468290-6E159FE9-12EC-4247-9B45-0864C3F7AF1A Q37708897-514D369B-7FF7-41B3-9E30-F1715484B1C4 Q37724647-6FA2A868-BEA4-430E-81DE-DE8F0D510290 Q38075499-91A302BB-B8C8-458B-9E86-33DBBE467627 Q38140697-A45C4559-1D5C-4118-A183-7B281538FD89 Q38210070-77A5336E-4404-424C-AE7D-FB67A5E5A317 Q38221886-B5B1475E-DE30-4DE2-A493-F2F0E083C02C Q38256334-81AF96F7-0E64-4E76-9368-9B9F8854570E Q38313697-323FE541-DB3B-4DA9-BFE4-77EB85F86EE7

P2860

HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature

http://www.wikidata.org/entity/Q34223664

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

HER2 as a Prognostic Marker in ...... is of Data from the Literature

@ast

HER2 as a Prognostic Marker in ...... is of Data from the Literature

@en

HER2 as a Prognostic Marker in ...... is of Data from the Literature

@nl

type

label

HER2 as a Prognostic Marker in ...... is of Data from the Literature

@ast

HER2 as a Prognostic Marker in ...... is of Data from the Literature

@en

HER2 as a Prognostic Marker in ...... is of Data from the Literature

@nl

prefLabel

HER2 as a Prognostic Marker in ...... is of Data from the Literature

@ast

HER2 as a Prognostic Marker in ...... is of Data from the Literature

@en

HER2 as a Prognostic Marker in ...... is of Data from the Literature

@nl

P1433

Q34223664-4E48EB26-80B2-47D9-8AFE-3C8E7BF5E78F

P1476

Q34223664-CD9769B3-75B2-49D0-AE07-5D280ECFB711

P2093

Q34223664-2F4D0D9F-2A44-4A70-A01A-679897B7C0F5

Q34223664-655D97C8-5641-4E5B-A82C-62F7F1D91AEC

P2860

Q34223664-055572CF-A048-4EA4-A9C8-F9C1E88C344A

Q34223664-126B3FAD-5BEC-435F-80E2-EFF9B96BE010

Q34223664-19C9A405-73C7-4E3B-B67B-014D7991FFE9

Q34223664-2495BB71-2F2A-43AF-8836-ACDB81AFDAE3

Q34223664-2D47A614-587F-48FD-9BAF-9DBAC56FD873

Q34223664-2FD72D15-8E81-4124-9C84-EC247D420097

Q34223664-30DE3374-8EF5-4DC3-8206-517051FED644

Q34223664-476D6F40-6BAC-4397-B165-265C6E174C50

Q34223664-484BBCAF-1C56-4D74-BA76-CCD1EA5D0E54

Q34223664-5F6A5F4B-BB8F-4A0F-BB68-FD9F396DFF9E

P304

Q34223664-85ADA4ED-533A-46CB-8258-CA2688775D50

P31

Q34223664-7DE9D8A4-5E2A-4D65-9BD3-3970AAD8FC46

P356

Q34223664-B1C2D5C4-A73B-4A3C-829A-37D234BB519B

P478

Q34223664-C09F2DD2-FE71-41ED-88CF-81DE72DEBFA7

P577

Q34223664-543A6FB2-F833-4299-9497-EE781AB6BE55

P5875

Q34223664-275DEB91-01AD-4D58-BB44-D5BC14C5BBB8

P698

Q34223664-46647705-6B04-48A4-A545-D61B85D978CB

P932

Q34223664-17299D8D-1E89-4C15-B10D-C9FCD91C0DD1

P356

P1433

Journal of Cancer

P1476

HER2 as a Prognostic Marker in ...... is of Data from the Literature

@en

P2093

Jan Trøst Jørgensen

http://www.w3.org/2001/XMLSchema#string

Maria Hersom

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer.

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

A study of HER2 gene amplification and protein expression in gastric cancer.

The prognostic significance of c-erbB-2 and p53 protein expressions in gastric carcinoma--a multivariate analysis of prognostic factors.

Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma.

Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization

Multivariate prognostic study on large gastric cancer.

P304

137-144

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7150/JCA.4090

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223963408

http://www.w3.org/2001/XMLSchema#string

P698

22481979

http://www.w3.org/2001/XMLSchema#string

P932

3319979

http://www.w3.org/2001/XMLSchema#string